Direct Oral Anticoagulants (DOACs) have revolutionized the management of thromboembolic disorders, offering alternatives to warfarin with more predictable pharmacokinetics and fewer monitoring requirements. For PharmD students, a deep understanding of these agents—including their mechanisms, indications, specific dosing considerations, and reversal strategies—is essential for ensuring safe and effective patient care in a rapidly evolving therapeutic landscape.
1. Dabigatran exerts its anticoagulant effect by directly inhibiting which of the following clotting factors?
- Factor Xa
- Thrombin (Factor IIa)
- Vitamin K epoxide reductase
- Platelet aggregation
Answer: Thrombin (Factor IIa)
2. Rivaroxaban, apixaban, and edoxaban are all members of which class of anticoagulants?
- Vitamin K antagonists
- Direct Thrombin Inhibitors
- Direct Factor Xa Inhibitors
- Low-Molecular-Weight Heparins
Answer: Direct Factor Xa Inhibitors
3. A major advantage of DOACs compared to warfarin is:
- The need for frequent routine laboratory monitoring
- Their long half-life, making missed doses less critical
- Their rapid onset of action and fewer drug-food interactions
- The availability of a single, universal reversal agent
Answer: Their rapid onset of action and fewer drug-food interactions
4. The approved reversal agent for dabigatran is:
- Protamine sulfate
- Vitamin K
- Idarucizumab
- Andexanet alfa
Answer: Idarucizumab
5. Andexanet alfa is a reversal agent specifically designed for which class of medications?
- Direct Thrombin Inhibitors
- Warfarin
- Factor Xa Inhibitors
- Unfractionated heparin
Answer: Factor Xa Inhibitors
6. Which DOAC should be taken with food to ensure adequate absorption?
- Apixaban
- Dabigatran
- Rivaroxaban (for doses of 15 mg and 20 mg)
- Edoxaban
Answer: Rivaroxaban (for doses of 15 mg and 20 mg)
7. DOACs are commonly used for stroke prevention in which of the following conditions?
- Peripheral artery disease
- Non-valvular atrial fibrillation
- Stable angina
- Essential hypertension
Answer: Non-valvular atrial fibrillation
8. When initiating treatment for an acute venous thromboembolism (VTE), which DOAC requires an initial period of parenteral anticoagulation before it can be started?
- Rivaroxaban
- Apixaban
- Edoxaban
- Dabigatran
Answer: Edoxaban
9. Dosing adjustments for most DOACs are primarily based on which patient parameter?
- Liver function
- Body mass index (BMI)
- Renal function (creatinine clearance)
- Blood pressure
Answer: Renal function (creatinine clearance)
10. Strong inhibitors of both P-glycoprotein (P-gp) and CYP3A4 can have what effect on the concentration of rivaroxaban or apixaban?
- Decrease their concentration
- Increase their concentration, raising the risk of bleeding
- No effect on their concentration
- Convert them to their active metabolites more quickly
Answer: Increase their concentration, raising the risk of bleeding
11. Unlike warfarin, routine monitoring of the anticoagulant effect of DOACs is generally:
- Required on a weekly basis
- Performed using the INR
- Not necessary due to their predictable pharmacokinetics
- Done by measuring platelet count
Answer: Not necessary due to their predictable pharmacokinetics
12. A key counseling point for a patient starting a DOAC is the importance of:
- Maintaining a consistent intake of Vitamin K
- Adherence, as a missed dose can quickly lead to loss of anticoagulant effect due to a short half-life
- Getting their INR checked every week
- Taking the medication only when they feel symptoms
Answer: Adherence, as a missed dose can quickly lead to loss of anticoagulant effect due to a short half-life
13. A patient is being transitioned from warfarin to a DOAC. The DOAC can typically be started when the patient’s INR is:
- Above 3.0
- Between 2.5 and 3.0
- Below 2.0 (or as specified by the manufacturer)
- The INR value does not matter for the transition
Answer: Below 2.0 (or as specified by the manufacturer)
14. A DOAC may be preferred over warfarin in a patient who:
- Has a stable TTR of 90%
- Has a mechanical heart valve
- Has difficulty with frequent INR monitoring or has an unstable INR
- Is taking strong P-gp and CYP3A4 inducers like rifampin
Answer: Has difficulty with frequent INR monitoring or has an unstable INR
15. One of the “expanded DOAC indications” includes use in combination with aspirin for certain patients with:
- A recent stroke
- Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
- A new diagnosis of hypertension
- A recent DVT
Answer: Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
16. For the treatment of VTE, both apixaban and rivaroxaban have an initial phase of:
- Parenteral bridge therapy
- Higher, more frequent dosing for the first 7-21 days
- Once-daily low-dose therapy
- INR monitoring
Answer: Higher, more frequent dosing for the first 7-21 days
17. What is a significant disadvantage of DOACs compared to warfarin?
- Slower onset of action
- Higher number of food interactions
- Higher drug acquisition cost and the need for renal dose adjustments
- The need for routine monitoring
Answer: Higher drug acquisition cost and the need for renal dose adjustments
18. The overview of DOAC therapy for a student pharmacist would include their mechanisms, indications, and:
- Reversal strategies
- Marketing budgets
- Manufacturing processes
- Chemical synthesis pathways
Answer: Reversal strategies
19. Which of the following is a direct thrombin inhibitor?
- Apixaban
- Rivaroxaban
- Edoxaban
- Dabigatran
Answer: Dabigatran
20. When managing a patient with a DOAC-related bleed, the first step is always to:
- Administer the reversal agent
- Discontinue the anticoagulant and provide supportive care
- Start a heparin infusion
- Check an INR
Answer: Discontinue the anticoagulant and provide supportive care
21. A patient on apixaban for atrial fibrillation is scheduled for a major surgery. The apixaban should be held for at least ________ before the procedure.
- 12 hours
- 24 hours
- 48 hours
- 72 hours
Answer: 48 hours
22. Which of the following drugs is a strong P-gp and CYP3A4 inducer that can significantly decrease DOAC levels?
- Amiodarone
- Ketoconazole
- Rifampin
- Diltiazem
Answer: Rifampin
23. The use of DOACs is generally not recommended in which patient population?
- Patients with non-valvular atrial fibrillation
- Patients with mechanical heart valves
- Patients undergoing knee replacement surgery
- Patients with a deep vein thrombosis
Answer: Patients with mechanical heart valves
24. A pharmacist’s role in DOAC therapy includes counseling on the risk of:
- Thrombosis
- Bleeding
- Adherence
- All of the above
Answer: All of the above
25. A review of DOAC literature for atrial fibrillation would compare the efficacy and safety of DOACs against which traditional therapy?
- Aspirin
- Clopidogrel
- Warfarin
- Heparin
Answer: Warfarin
26. Dabigatran is formulated as a prodrug and is available in a capsule that should not be:
- Taken with food
- Stored in its original container
- Crushed, chewed, or opened
- Taken by patients with a history of VTE
Answer: Crushed, chewed, or opened
27. A specific laboratory test that can be used to estimate the effect of a Factor Xa inhibitor is a(n):
- aPTT
- INR
- Anti-Xa level
- Platelet count
Answer: Anti-Xa level
28. An “overview of DOAC therapy” for a practitioner would emphasize their role as an alternative to:
- Warfarin
- Statins
- Beta-blockers
- ACE inhibitors
Answer: Warfarin
29. For VTE treatment and prevention of recurrence, DOACs are often preferred due to:
- Their complicated dosing regimens
- The need for frequent blood draws
- Their efficacy and improved safety profile regarding intracranial hemorrhage compared to warfarin
- Their low cost
Answer: Their efficacy and improved safety profile regarding intracranial hemorrhage compared to warfarin
30. Which of these DOACs directly binds to the active site of Factor Xa?
- Dabigatran
- Warfarin
- Apixaban
- Heparin
Answer: Apixaban
31. The choice of which DOAC to use in a patient may depend on:
- Renal function
- The specific indication
- Potential drug interactions
- All of the above
Answer: All of the above
32. The “peri-procedural anticoagulation management” of DOACs is generally simpler than warfarin because:
- DOACs have a much shorter half-life
- DOACs do not need to be stopped before surgery
- Warfarin has a rapid offset of action
- DOACs do not increase bleeding risk
Answer: DOACs have a much shorter half-life
33. Apixaban has been studied and shown to be an effective option for the treatment of VTE associated with which condition?
- Hypertension
- Diabetes
- Cancer
- Asthma
Answer: Cancer
34. A patient misses a dose of their twice-daily apixaban. What is the correct advice?
- Skip the dose and wait for the next scheduled dose
- Take the missed dose as soon as they remember, and then continue with the regular schedule
- Double the next scheduled dose
- Stop taking the medication permanently
Answer: Take the missed dose as soon as they remember, and then continue with the regular schedule
35. A key learning objective for a student pharmacist regarding DOACs is to understand their use in:
- Atrial fibrillation and VTE treatment
- Only rare, orphan diseases
- Non-prescription settings
- Compounding sterile preparations
Answer: Atrial fibrillation and VTE treatment
36. Unlike warfarin, the anticoagulant effect of DOACs is less affected by:
- Renal function
- Dietary intake of Vitamin K
- CYP2C9 inducers
- Age
Answer: Dietary intake of Vitamin K
37. Before prescribing a DOAC, it is essential to obtain a baseline:
- INR
- Liver function panel
- Renal function assessment (e.g., serum creatinine)
- Lipid panel
Answer: Renal function assessment (e.g., serum creatinine)
38. The selection of a reversal agent for a DOAC depends on:
- Which specific DOAC the patient is taking
- The patient’s age
- The patient’s insurance plan
- The time of day
Answer: Which specific DOAC the patient is taking
39. A DOAC PowerPoint assignment for students would likely involve a deep dive into:
- A specific clinical question or comparison of DOACs based on literature
- The history of warfarin
- The manufacturing process of DOACs
- The marketing strategies for a new DOAC
Answer: A specific clinical question or comparison of DOACs based on literature
40. A pharmacist receives a prescription for dabigatran for a patient with a CrCl of 25 mL/min. The pharmacist should:
- Dispense the prescription as written
- Question the appropriateness of the dose or drug due to severe renal impairment
- Recommend switching to warfarin without consulting the prescriber
- Tell the patient the drug is not effective
Answer: Question the appropriateness of the dose or drug due to severe renal impairment
41. The term “direct” in Direct Oral Anticoagulants refers to their action of:
- Binding directly to their target clotting factor
- Being prescribed directly by a pharmacist
- Being available for direct-to-consumer purchase
- Having a direct effect on blood pressure
Answer: Binding directly to their target clotting factor
42. Which of the following is NOT a DOAC?
- Apixaban
- Warfarin
- Rivaroxaban
- Dabigatran
Answer: Warfarin
43. A patient on dabigatran needs emergency surgery. The administration of idarucizumab would be expected to:
- Slowly reverse the anticoagulant effect over 24 hours
- Rapidly reverse the anticoagulant effect of dabigatran
- Increase the anticoagulant effect
- Have no effect on dabigatran’s activity
Answer: Rapidly reverse the anticoagulant effect of dabigatran
44. Extended treatment of VTE (beyond 3-6 months) with a DOAC is done to:
- Cure the patient of their hypercoagulable state
- Prevent the recurrence of VTE
- Monitor for long-term side effects
- Ensure the patient remains on a high-cost medication
Answer: Prevent the recurrence of VTE
45. Which DOAC is a prodrug that is converted to its active form after absorption?
- Apixaban
- Rivaroxaban
- Dabigatran etexilate
- Edoxaban
Answer: Dabigatran etexilate
46. The primary safety concern with all anticoagulants, including DOACs, is the risk of:
- Hyperglycemia
- Hypertension
- Bleeding
- Thrombosis
Answer: Bleeding
47. A pharmacist educating a patient on rivaroxaban for VTE treatment should emphasize taking the 15 mg and 20 mg tablets:
- On an empty stomach
- With a full meal
- Only at bedtime
- With a large glass of grapefruit juice
Answer: With a full meal
48. In the peri-procedural setting, restarting a DOAC after a surgery with a high risk of bleeding should be:
- Done immediately after the procedure ends
- Delayed for 24-72 hours, depending on the procedure and bleeding risk
- Done with a large loading dose
- Switched to warfarin for one week
Answer: Delayed for 24-72 hours, depending on the procedure and bleeding risk
49. An understanding of DOAC literature is important for a pharmacist to:
- Critically evaluate new clinical trials and apply them to patient care
- Memorize the price of each DOAC
- Learn how to compound DOACs from powder
- Market DOACs to physicians
Answer: Critically evaluate new clinical trials and apply them to patient care
50. The development of DOACs represents a major advance in anticoagulation therapy by providing options that are:
- More effective and safer for all patients in every situation
- Less expensive than warfarin
- Often more convenient and safer in certain aspects compared to warfarin
- Free from any risk of bleeding
Answer: Often more convenient and safer in certain aspects compared to warfarin
